The U.S. Supreme Court ruled today that the Federal Trade Commission can proceed with its "pay-for-delay" case, which argues that pharmaceutical manufacturers illegally restrict competition by reaching deals with generic drug companies to keep cheaper versions of drugs off the market.
The commission had brought a case which alleged that the decision of Solvay Pharmaceuticals, a subsidiary of Abbott Laboratories, to pay competing drug companies in exchange for an agreement not to market generic versions of a testosterone drug was illegal. ...
Read more: BREAKING: Supreme Court backs FTC in 'pay-for-delay' case | Modern Healthcare http://www.modernhealthcare.com/arti...#ixzz2WUFD1Xf1
Jun 17, '13
by OCNRN63, RN
Quote from tewdles
and the exclusive for profit model of health care encourages this...
fortunately we are talking here about testosterone and not 5FU, which also has a new, more expensive, non-generic, option.
Big Pharma...bless their greedy little hearts. So good at re-inventing the wheel.
Last edit by OCNRN63 on Jun 17, '13